skip to content
  1. Home
  2. >
  3. Investment Q&A
You can view 3 more answers this month. Sign up for a free trial for unlimited access.

Investment Q&A

Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.

Q: Would you say this is an accurate way to characterize Knight Therapeutics?

The Globe and Mail reports in its Monday edition that the markets are on edge and trend followers are running for the exits. The Globe's Norman Rothery writes in the Inside the Market column that it is hard for companies to raise money while fear stalks the land. Mr. Rothery says they risk becoming zombie stocks that shamble around a bit before keeling over. He says even in good times, firms with negative earnings fare poorly and are, as a group, best avoided. For the current column, Mr. Rothery says he focused on stocks that are, potentially, in much more dire circumstances. To find them he looked at earnings before interest, taxes, depreciation and amortization or EBITDA. It is bad enough to fall into the red after paying normal and recurring business expenses such as interest and taxes and other expenses; it can be deadly having negative earnings even before these essentials are paid for. Companies with negative EBITDAs are in a particularly precarious position and may be zombies. Matters get worse when the markets tumble and it becomes next to impossible to borrow money or to sell stock. Mr. Rothery's potential zombie stocks are Hexo, Knight Therapeutics, Advanz Pharma, Katanga Mining and Paramount Resources.

Thanks as always,

Rob
Read Answer Asked by Robert on December 14, 2018
Q: According to a Morningstar report, year to date earnings per share are negative; yet another report I saw seems to contradict this. What do you see as this year's EPS?
Also what is your current projection for earnings over the next two years? And what are possible events that could affect your estimates either up or down?
Read Answer Asked by John on December 13, 2018
Q: Hi 5i!
Pretty tepid reaction to yesterday's news. Even on today's broad market bounce, the stock doesn't seem to get any traction, holding barely into positive territory. And after a 50%+ fall from its june high, what are your thoughts on such negativity on TSGI? Has the fundamentals changes this much in 5-6 months? In hindsight, this feels like such a fad...

Anyways, thanks for 2018 and a Happy Holidays to all of you folks at 5i !!!
Read Answer Asked by Stéphane on December 13, 2018
Q: What are your thoughts on ABT? Is this a stock that I can buy and hold? Thanks!
Read Answer Asked by Keith on December 12, 2018
Q: Hi, Sylogist share price has retreated to $12.50 level, from the high of $14.50, a few weeks ago. Company increased the quarterly dividend by 18.75% recently and had positive notes on its outlook. It also continues buy back its shares, gradually ( in addition to small insider buying). Cormark bumped its price target to $18 and upgraded stock to Top Pick in September, 2018. What's your current view on the company ? Should the recent softness be attributed simply to markets and low liquidity of the stock ? Is it a good candidate to add for dividend and growth ? Thanks
Read Answer Asked by rajeev on December 12, 2018
Q: Hi

I have not had time to do the research lately, but what is happening to SIS. I bought it at $16.60 abut a month ago when it was showing good potential and growth. I know that the stock market is turbulent right now, and affecting good companies negatively, but did I miss something important about this company. I bought 300 shares, should I hold on to them or is there something tragic looming on the horizon for SIS.
Read Answer Asked by Robert on December 12, 2018
Q: Hi, share price has declined to $33.86, from a high of $40.88, only a few weeks ago.
This company has a very low share count of 10.9 mln shares with a float of just 7.3 mln. Fairly large holding by insiders/institutions - 35-40%. Decent dividend yield 3.90%. Company's revenue is almost equally distributed between US and Canada. There has also been some nominal insider buying reported recently. Is it just the market volatility and illiquid nature of stock or any other reason for recent softness, in your view? Should we buy/add for dividend and growth ? Thanks
Read Answer Asked by rajeev on December 12, 2018